WIN-Partners Co., Ltd.

Tokyo Stock Exchange 3183.T

WIN-Partners Co., Ltd. EBITDA Margin for the year ending March 31, 2024: 3.78%

WIN-Partners Co., Ltd. EBITDA Margin is 3.78% for the year ending March 31, 2024, a -13.82% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

WIN-Partners Co., Ltd. EBITDA Margin for the year ending March 31, 2023 was 4.39%, a 3.54% change year over year.
WIN-Partners Co., Ltd. EBITDA Margin for the year ending March 31, 2022 was 4.24%, a 7.55% change year over year.
WIN-Partners Co., Ltd. EBITDA Margin for the year ending March 31, 2021 was 3.94%, a -10.59% change year over year.
WIN-Partners Co., Ltd. EBITDA Margin for the year ending March 31, 2020 was 4.41%, a -12.06% change year over year.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

Tokyo Stock Exchange: 3183.T

WIN-Partners Co., Ltd.

CEO	Mr. Hideumi Akizawa
IPO Date	Sept. 16, 2002
Location	Japan
Headquarters	Kyobashi Edogrand
Employees	629
Sector	Healthcare
Industries Medical Instruments 3D Printing Biotechnology Hardware & Electronics

Description

WIN-Partners Co., Ltd., through its subsidiaries, distributes medical devices to medical institutions primarily in Japan. The company offers percutaneous transluminal coronary angioplasty balloon catheters, drug-eluting stents, and intravascular ultrasound catheters; pacemakers, implantable cardioverter defibrillators, cardiac resynchronization therapy defibrillators, and ablation catheters; and stent grafts, transcatheter heart valves, and mechanical heart valves. It also provides peripheral vascular stents, carotid artery stents, and embolic coils; and insulin pumps, as well as continuous glucose monitoring and magnetic resonance imaging equipment. The company was founded in 1973 and is headquartered in Tokyo, Japan.

Key trends

Past 5 years